Fabiola R. Arredondo
Known title: DirectorCIK: 0001554779
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FICO posts record quarter, faces regulatory focus, gains UWM tie. The company announced a record quarterly performance, but analysts highlighted ongoing regulatory scrutiny that could affect future operations. A recent commitment from United Wholesale Mortgage to use FICO scores was noted as a potential catalyst for valuation considerations. Raymond James kept an outperform view while adjusting its price target, reflecting mixed sentiment among analysts.
Transaction History
| CPB | ▲ Buy | Grant | 2,204 | $0 | 9/25/2026 | View on chart |
| CPB | ▲ Buy | Grant | 1,855 | $0 | 6/29/2026 | View on chart |
| CPB | ▲ Buy | Grant | 1,925 | $0 | 3/30/2026 | View on chart |
| FICO | ▲ Buy | Option Exercise | 154 | $0 | 3/4/2026 | View on chart |
| CPB | ▲ Buy | Grant | 1,516 | $0 | 12/29/2025 | View on chart |
| CPB | ▲ Buy | Grant | 1,325 | $0 | 9/25/2025 | View on chart |
| CPB | ▲ Buy | Grant | 1,379 | $0 | 6/26/2025 | View on chart |
| CPB | ▲ Buy | Grant | 1,079 | $0 | 3/27/2025 | View on chart |
| CPB | ▲ Buy | Grant | 970 | $0 | 12/30/2024 | View on chart |
| CPB | ▲ Buy | Grant | 813 | $0 | 9/26/2024 | View on chart |
| CPB | ▲ Buy | Grant | 881 | $0 | 6/26/2024 | View on chart |
| CPB | ▲ Buy | Grant | 912 | $0 | 3/27/2024 | View on chart |
| FICO | ▲ Buy | Option Exercise | 344 | $0 | 2/14/2024 | View on chart |
| CPB | ▲ Buy | Grant | 906 | $0 | 12/28/2023 | View on chart |
| CPB | ▲ Buy | Grant | 944 | $0 | 9/29/2023 | View on chart |
| CPB | ▲ Buy | Grant | 856 | $0 | 6/29/2023 | View on chart |
| CPB | ▲ Buy | Grant | 716 | $0 | 3/30/2023 | View on chart |
| FICO | ▲ Buy | Option Exercise | 369 | $0 | 3/1/2023 | View on chart |
| FICO | ▲ Buy | Option Exercise | 475 | $0 | 3/1/2023 | View on chart |
| CPB | ▲ Buy | Grant | 654 | $0 | 12/29/2022 | View on chart |
| CPB | ▲ Buy | Grant | 788 | $0 | 9/29/2022 | View on chart |
| CPB | ▲ Buy | Grant | 766 | $0 | 6/29/2022 | View on chart |
| CPB | ▲ Buy | Grant | 840 | $0 | 3/30/2022 | View on chart |
| FICO | ▲ Buy | Option Exercise | 370 | $0 | 3/1/2022 | View on chart |
| CPB | ▲ Buy | Grant | 858 | $0 | 12/30/2021 | View on chart |
| CPB | ▲ Buy | Grant | 865 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Campbell's Shares Near 52-Week Low Amid Dividend Scrutiny
Recent articles examine Campbell's stock as a potential value trap, noting a 16% decline in September and ongoing pressure on the company's valuation. The stock is currently trading near its 52-week low, with analysts debating whether its 3.6% dividend yield justifies the current price. This context highlights growing skepticism among investors regarding the company's ability to sustain its financial performance.
Campbell's Shares Near 52-Week Low Amid Dividend Scrutiny. Recent articles examine Campbell's stock as a potential value trap, noting a 16% decline in September and ongoing pressure on the company's valuation. The stock is currently trading near its 52-week low, with analysts debating whether its 3.6% dividend yield justifies the current price. This context highlights growing skepticism among investors regarding the company's ability to sustain its financial performance.